Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.06
- Piotroski Score 6.00
- Grade Buy
- Symbol (ZH)
- Company Zhihu Inc.
- Price $3.49
- Changes Percentage (-2.24%)
- Change -$0.08
- Day Low $3.48
- Day High $3.57
- Year High $6.24
Zhihu Inc. operates an online content community in the People's Republic of China. Its community allows people to seek inspiration, find solutions, make decisions, and have fun. The company also offers technology, business support, and consulting services; information transmission, software, and information technology services; information and marketing services; vocational training; and internet services, as well as holds audio-visual permit. The company was founded in 2010 and is headquartered in Beijing, the People's Republic of China.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/26/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.19
- Trailing P/E Ratio -2.85
- Forward P/E Ratio -2.85
- P/E Growth -2.85
- Net Income $-843,641,000
Income Statement
Quarterly
Annual
Latest News of ZH
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
UK regulator approves second Alzheimer's drug in months but government won't pay for it
The UK approved the Alzheimer's drug Kisunla, but won't fund it due to cost concerns. Another drug, Leqembi, faced similar issues. Kisunla shows promise in slowing disease progression but lacks eviden...
By AP NEWS | 16 hours ago -
Alzheimer's drug rejected for widespread NHS use in England
The new Alzheimer's drug, donanemab, has been deemed not cost-effective for the NHS by the health spending watchdog in England. Despite its potential to slow cognitive decline, the drug's high cost do...
By The Guardian | 18 hours ago -
Marriott to bring The Luxury Collection and AC Hotel brands to Shenzhen
Marriott International partners with Shum Yip Holdings to introduce Luxury Collection Hotel and AC Hotel to Shenzhen, China by November 2028. The hotels will cater to business and leisure travelers, o...
By Yahoo! Finance | 2 days ago